News
Bristol Myers' schizophrenia drug Cobenfy stumbles as adjunctive treatment, denting blockbuster plan
Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. | Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity,
Bristol Myers’ schizophrenia drug fails key study
Bristol Myers Squibb’s schizophrenia drug Cobnefy failed to meet a primary goal in a phase 3 trial, possibly clouding the drug’s future development. The trial evaluated Cobnefy as an add-on therapy to existing atypical antipsychotics in adults with uncontrolled schizophrenia symptoms,
Although schizophrenia presents differently in each individual, symptoms are typically classified into three different categories: positive, negative and cognitive symptoms. “Positive ...
19h
Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy ...
Clinical Trials Arena on MSN1d
BMS’ schizophrenia therapy fails in Phase III trial as an adjunctive treatmentThe therapy showed a two-point reduction in total PANSS score at week six against placebo with atypical antipsychotic.
Research highlights the potential for modifying the chemical structures of psychedelics to produce analogues with improved ...
Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point ...
Explore how LB Pharmaceuticals is revolutionizing the pharma industry with its innovative therapies for neuropsychiatric ...
Neurocrine Biosciences' valbenazine shows promise as an adjunctive therapy for Schizophrenia, with phase 3 data expected in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback